Antidepressants for depression in schizophrenia: when good-enough evidence is good enough


Carmine Pariante is positive about a recent systematic review and meta-analysis of antidepressants for the treatment of depression in schizophrenia.

[read the full story...]

Antipsychotics for acute treatment of first episode schizophrenia


Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode schizophrenia.

[read the full story...]

Antipsychotic efficacy measured by real-world observational study


Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.

[read the full story...]

Schizophrenia, antipsychotics and quality of life: measuring the important things


Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.

[read the full story...]

Lithium for bipolar disorder: the best maintenance mood stabiliser protection against self-harm and suicide?


Michael Ostacher provides a robust appraisal of a recent UK cohort study that suggests bipolar disorder patients taking lithium had reduced self-harm and unintentional injury rates, when compared with patients taking valproate, olanzapine or quetiapine.

[read the full story...]

Lamotrigine, quetiapine and folic acid for bipolar depression: the CEQUEL trial


Michael Ostacher considers the findings of the CEQUEL trial, which asks: Does lamotrigine treat bipolar depression when added to quetiapine, and does adding folic acid help any more?

[read the full story...]

Biological pathways, antipsychotics and schizophrenia


Murtada Alsaif summarises a small cohort study that uses shotgun mass spectrometry proteomic profiling to unravel the molecular pathways involved with antipsychotic response in people with schizophrenia.

[read the full story...]

The antipsychotic drugs don’t work for anorexia nervosa

Refusing pills

Helen Bould appraises a recent meta-analysis of second-generation antipsychotics for anorexia nervosa, which finds that the drugs don’t lead to weight gain or improve eating disorder symptoms. So why are antipsychotics being used in this group of patients?

[read the full story...]

Quetiapine for schizophrenia: more transparency needed in clinical trial reporting


Andrew Shepherd reports on a recent systematic review, meta-analysis and reappraisal of Quetiapine for schizophrenia, which concludes that Quetiapine IR has a small beneficial effect on psychotic symptoms, but also leads to weight gain and sedation.

[read the full story...]

Are treatments for bipolar disorder cost-effective?


Chris Sampson reports on a recent systematic review and critical appraisal of economic evaluations in bipolar disorder. He finds that there’s a pressing need for new studies, especially discrete event simulations.

[read the full story...]